Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -71.57% | -56.36% | -45.13% | -35.86% | -11.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.57% | -56.36% | -45.13% | -35.86% | -11.19% |
| Cost of Revenue | 25.04% | 23.98% | 29.03% | 31.59% | 26.39% |
| Gross Profit | -30.47% | -29.13% | -35.43% | -37.64% | -29.48% |
| SG&A Expenses | -6.69% | 26.70% | 26.09% | 79.08% | 70.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.79% | 25.36% | 27.52% | 53.67% | 47.12% |
| Operating Income | -9.77% | -27.86% | -30.45% | -57.79% | -49.57% |
| Income Before Tax | 61.18% | -59.12% | -118.01% | -119.43% | -114.92% |
| Income Tax Expenses | 176.77% | 1,318.16% | -13.69% | 28.53% | 124.03% |
| Earnings from Continuing Operations | 45.47% | -75.77% | -118.90% | -120.42% | -116.05% |
| Earnings from Discontinued Operations | -- | -100.00% | 426.88% | 297.95% | 218.37% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -46.88% | 15.60% | 40.60% | 65.28% | 56.94% |
| Net Income | -74.30% | -593.91% | -107.77% | -110.36% | -103.95% |
| EBIT | -9.77% | -27.86% | -30.45% | -57.79% | -49.57% |
| EBITDA | -10.82% | -29.32% | -32.04% | -61.03% | -53.22% |
| EPS Basic | -84.69% | -751.06% | -109.22% | -111.82% | -104.46% |
| Normalized Basic EPS | -69.77% | -92.58% | -72.14% | -82.61% | -29.31% |
| EPS Diluted | -145.95% | -744.25% | -109.92% | -112.63% | -104.84% |
| Normalized Diluted EPS | -61.72% | -94.52% | -76.15% | -87.26% | -29.81% |
| Average Basic Shares Outstanding | -4.86% | -7.72% | -9.22% | -8.48% | -7.40% |
| Average Diluted Shares Outstanding | -2.60% | -9.11% | -11.79% | -11.05% | -7.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |